Publication:
Inhaled corticosteroids- effects on biomarkers in exhaled breath condensate and blood in patients newly diagnosed with asthma who smoke

Simple item page
dc.contributor.authorDUMAN, Berna
dc.contributor.authorBÖREKÇİ, Şermin
dc.contributor.authorAkdeniz, Nilgun
dc.contributor.authorGazioglu, Sema Bilgic
dc.contributor.authorDeniz, Gunnur
dc.contributor.authorGEMİCİOĞLU, Bilun
dc.contributor.institutionauthorDUMAN, BERNA
dc.date.accessioned2021-08-24T20:59:08Z
dc.date.available2021-08-24T20:59:08Z
dc.date.issued2021-08-01T00:00:00Z
dc.description.abstractObjective Exposure to cigarette smoke complicates the treatment and management of asthma through a variety of inflammatory effects. This study aimed to investigate the differences between newly diagnosed cases of asthma in smokers and nonsmokers in terms of localized and systemic biomarkers following treatment with inhaled corticosteroids (ICS) or ICS in combination with a long-acting beta 2 agonist (LABA). Methods Specimens of exhaled breath condensate (EBC) from newly diagnosed patients with asthma were used to quantify inflammation in the airways, while blood samples were used to assess systemic inflammation. In both samples, the levels of IL-6, LTB4, LTD4, and 8-isoprostane were measured and these were repeated after 3 months of treatment with ICS or ICS + LABA. Results Of the 20 patients, 10 (50%) were nonsmokers with asthma (NSA) and 10 (50%) smokers with asthma (SA). There was no statistically significant difference in the blood or EBC levels of IL-6, LTB4, LTD4, or 8-isoprostane between the groups prior to treatment. Only the decrease in 8-isoprostane level in the EBC samples was found to be significantly greater in the NSA group after treatment (for smokers, the change was 2.91 +/- 23.22, while for nonsmokers it was -22.72 +/- 33.12, p = 0.022). Post-treatment asthma control was significantly better in the NSA group (p = 0.033). Conclusion Monitoring the alterations in 8-isoprostane levels in EBC in patients with asthma who smoke may be helpful in deciding on therapeutic management and switching treatments. Asthma control was better in nonsmokers than in smokers.
dc.identifier.citationDUMAN B., BÖREKÇİ Ş., Akdeniz N., Gazioglu S. B. , Deniz G., GEMİCİOĞLU B., -Inhaled corticosteroids- effects on biomarkers in exhaled breath condensate and blood in patients newly diagnosed with asthma who smoke-, JOURNAL OF ASTHMA, 2021
dc.identifier.doi10.1080/02770903.2021.1962341
dc.identifier.pubmed34376110
dc.identifier.scopus85112570164
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29264
dc.identifier.wosWOS:000685014300001
dc.titleInhaled corticosteroids- effects on biomarkers in exhaled breath condensate and blood in patients newly diagnosed with asthma who smoke
dc.typeArticle
dspace.entity.typePublication
local.avesis.id402b9856-d2e8-4293-9f98-f15c2b9db2e2
local.publication.isinternational1
relation.isAuthorOfPublicationa4644139-f5cb-4cfc-a875-3d316fe38536
relation.isAuthorOfPublication.latestForDiscoverya4644139-f5cb-4cfc-a875-3d316fe38536
Files
Collections
Yayınlar - Eserler